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Abstract
Background: Propofol is widely used for both short-term anesthesia and long-term sedation. It
has unusual pharmacokinetics because of its high lipid solubility. The standard approach to
describing the pharmacokinetics is by a multi-compartmental model. This paper presents the first
detailed human physiologically based pharmacokinetic (PBPK) model for propofol.
Methods: PKQuest, a freely distributed software routine http://www.pkquest.com, was used for
all the calculations. The "standard human" PBPK parameters developed in previous applications is
used. It is assumed that the blood and tissue binding is determined by simple partition into the
tissue lipid, which is characterized by two previously determined set of parameters: 1) the value of
the propofol oil/water partition coefficient; 2) the lipid fraction in the blood and tissues. The model
was fit to the individual experimental data of Schnider et. al., Anesthesiology, 1998; 88:1170 in
which an initial bolus dose was followed 60 minutes later by a one hour constant infusion.
Results: The PBPK model provides a good description of the experimental data over a large range
of input dosage, subject age and fat fraction. Only one adjustable parameter (the liver clearance) is
required to describe the constant infusion phase for each individual subject. In order to fit the bolus
injection phase, for 10 or the 24 subjects it was necessary to assume that a fraction of the bolus
dose was sequestered and then slowly released from the lungs (characterized by two additional
parameters). The average weighted residual error (WRE) of the PBPK model fit to the both the
bolus and infusion phases was 15%; similar to the WRE for just the constant infusion phase obtained
by Schnider et. al. using a 6-parameter NONMEM compartmental model.
Conclusion: A PBPK model using standard human parameters and a simple description of tissue
binding provides a good description of human propofol kinetics. The major advantage of a PBPK
model is that it can be used to predict the changes in kinetics produced by variations in physiological
parameters. As one example, the model simulation of the changes in pharmacokinetics for morbidly
obese subjects is discussed.
Background
Propofol is widely used for the induction and mainte-
nance of anesthesia and as a sedative in intensive care
units where it is given as a constant intravenous infusion
for periods of many days. In addition to its clinical impor-
tance, propofol provides a valuable model for under-
standing the human pharmacokinetics of agents that are
concentrated in fat. Propofol has an oil/water partition
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coefficient (Koil) of about 4700 [1], one of the largest of
any pharmacological agent. In comparison, the highly
lipophilic volatile anesthetics, such as halothane, have a
Koil of less than 300 [2]. Because of this large fat partition,
propofol is highly concentrated in adipose tissue where it
has slow uptake and release kinetics.
This paper presents the first detailed physiologically based
pharmacokinetic (PBPK) description of human propofol
pharmacokinetics. The model describes the pharmacoki-
netics in terms of realistic human parameters, such as the
organ blood flow and the tissue/blood partition. The
PBPK model is implemented in PKQuest, a new software
routine that has now been applied to more than 25 differ-
ent solutes with a wide range of pharmacokinetic proper-
ties [3-9].
The major limitation in most human PBPK models is the
uncertainty in the values used for the tissue/blood parti-
tion coefficients, which cannot be directly measured and
are usually based on uncertain extrapolations from ani-
mal measurements. In general, the tissue partition of sol-
utes has a complex dependence on protein and lipid
binding and can vary markedly from tissue to tissue [10-
13]. This means that the PBPK model is dependent on a
large number of individual tissue partition coefficients
that are not well characterized and, effectively, become
adjustable model parameters. However, the highly fat sol-
uble non-polar solutes, such as the volatile anesthetics,
are a special case. Their tissue/blood partition is domi-
nated by simple, non-specific partition into the tissue
lipid. In a previous application of PKQuest to the volatile
anesthetics [4], it was shown that the water/tissue parti-
tion could be directly determined just from a knowledge
of the fraction of lipid in the different tissues and the value
of lipid/water partition coefficient (Koil). This means that
once the tissue lipid fractions are known (which are not
solute dependent), the tissue/blood partition coefficient
for any solute of this type is completely characterized by
knowledge of the just the one physical parameter, the Koil.
The PBPK modeling of solutes of this type is not only
greatly simplified, but one can have more confidence in
the model predictions because of the elimination of most
of the adjustable parameters.
It is assumed here that this same approach can be applied
to propofol. The tissue/blood partition coefficient is equal
to the ratio of the tissue/water and blood/water partition:
The tissue/water partition is determined from the fraction
of lipid in the tissue and the Koil of propofol. The blood/
water partition is determined from experimental measure-
ments of the fraction of propofol that is free (unbound) in
blood – defined by the parameter freepl.. Since there is
large individual variation in the value of freepl [14-19]
one might regard it as an adjustable parameter that varied
from subject to subject. However, it was found that the
PBPK model adequately predicted the individual results
using one average value of freepl for all subjects. Only one
parameter was adjusted for each subject – the intrinsic
liver clearance. All the other PBPK parameters are identical
to those that have been used previously in the application
of PKQuest to a variety of solutes. A detailed description
of the propofol PBPK model is provided in the Methods
Section.
This PBPK model is evaluated by applying it to the exper-
imental data of Schnider et. al. [20]. This data describes
the arterial pharmacokinetics of propofol in 24 healthy
volunteers with ages varying from 24–81 years, and at 4
different doses. Each subject was given an initial bolus
dose, followed 60 minutes later by a constant 60-minute
infusion. In the original publication, the pharmacokinet-
ics for the constant infusion phase was interpreted in
terms of a 6 parameter compartmental model using NON-
MEM. Surprisingly, the kinetic parameters from the con-
stant infusion phase were poor predictors of the kinetics
following the bolus injection in the same subject. This
suggested that there was some systematic difference
between the bolus and infusion kinetics, and effects such
as early recirculation, a propofol induced change in liver
blood flow or pulmonary sequestration were listed as pos-
sible explanations. This new PBPK analysis suggests that
pulmonary sequestration is the major factor responsible
for this discrepancy. The propofol is formulated as a lipid
emulsion because it has a low aqueous solubility. In some
subjects, a significant fraction of the bolus emulsion (0 –
60%) is sequestered in its first pass through the lung, and
then slowly released. When a quantitative model (with
two additional adjustable parameters) of this sequestra-
tion is incorporated into the PBPK model, a single set of
PBPK parameters provides a good description of both the
bolus and constant infusion phases.
Methods
Experimental data
The methodology for the data collection and analysis was
described in detail in the previous publication of Schnider
et. al. [20]. Briefly, 24 volunteers in 3 age groups (18–34;
35–65; and >65 years) of 8 each were selected. The indi-
vidual subjects will be identified as, eg, Subject # 1–5
where the first number refers to the age group (1: 18–34
years, etc.) and the second number is the individual
number for that group. Each subject was given an initial
bolus (≈  20 second) dose (2 mg/kg for subjects < 65; 1
mg/kg for subjects >65) followed 60 minutes later by a
constant 60 minute infusion of 25, 50, 100 or 200 µg/kg/
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min. Arterial blood samples were taken at 0, 1, 2, 4, 8, 16,
30, 60, 62, 64, 68, 76, 90, 120, 122, 124, 136, 150, 180,
240, 300 and 600 minutes and the arterial plasma propo-
fol concentration was determined. Each subject was stud-
ied on two separate visits, using either propofol with or
without EDTA under otherwise identical infusion condi-
tions. Since there was no significant difference with or
without EDTA, the data from these two experiments were
averaged and were used as the individual data that was fit-
ted with the PBPK model.
The percent body fat for each subject was determined
using the regression equation of Gallagher et. al. [21] with
an additional correction for Asians [22]:
where Sex is 0 for females and 1 for males, Asian is 1 for
Asians and 0 for others, Age is in years and BMI = weight/
height2 (kg/m2). Although the only value that is directly
used in the PBPK calculation for each subject is the per-
cent fat, the age, weight, sex, height and ethnicity enter as
covariate parameters through eq. (2).
Description of the PBPK tissue model for propofol
The PBPK model is identical to the one that has been used
in previous applications of PKQuest (fig. 1). The model
parameters (organ blood flow, volume, etc.) are identical
to those used in previous applications of PKQuest [3-9].
The connective tissue is divided between two organs: "ten-
don" with a relatively low blood flow, and "other" with a
higher blood flow [8]. The PBPK values for the tissue
weight, blood flow and fraction lipid are listed in Table 1.
A major limitation of this PBPK analysis is that a constant
set of "standard human" resting organ blood flow is
assumed and any hemodynamic changes associated with
the uptake and washout of propofol are ignored. The
experimental observation that cardiac output is either
unchanged [23,24] or only slightly decreased [25,26] with
short term propofol supports this assumption. However,
Sellgren et. al. [25,26] reported that propofol produced
large changes in peripheral blood flow which would sug-
gest that there may be a significant redistribution in the
organ blood flow that is ignored in this PBPK model.
The only PBPK features that must be uniquely specified
for propofol are the tissue/blood partition coefficients.
The free (unbound) water concentration (c, amount/liter
water) plays a central role in the PBPK calculations (see
[6] for details). For example, at equilibrium, c will have
the same value in all tissues and blood and the total
(measured) concentration (C, amount/kg) is related to c
by:
where vw
i (liters/kg) is the water fraction in tissue i and fwi
is the fraction of the total solute that is free in the water
phase. The parameter fwi characterizes the equilibrium tis-
sue/blood partition coefficients:
Schematic diagram of the PBPK model Figure 1
Schematic diagram of the PBPK model. The organ "portal" 
refers to all the organs drained by the portal vein. The con-
nective tissue is divided between two organs: "tendon" with a 
relatively low blood flow and "other" with a higher blood 
flow.
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The tissue/blood ratio determines the "effective" volume
of the different tissues and the overall volume of
distribution.
As discussed in the Background section, it is assumed that
the propofol tissue concentration depends simply on the
propofol partition in the tissue water and fat:
where vw
i and vf
i are water and fat fractions in tissue i, ci is
the free water concentration, Cf is the fat concentration
and Koil is the oil/water partition coefficient (= Cf/c). The
values used for the tissue fat fraction (vf
i, Table 1) are iden-
tical to those used in the previous application of PKQuest
to the pharmacokinetics of the volatile anesthetics [4].
They were determined from in vitro measurements of
human tissue/air partition coefficients for a number of
volatile anesthetics with a wide range of oil/air and water/
air partition. [See Additional file 1 for a description of the
experimental basis for this set of values of vf]. The value
used for Koil of propofol was 4715, which was determined
by Weaver et. al. [1] from measurements of the water/
Diprivan partition and the triglyceride concentration in
Diprivan. This is similar to the value of the octanol/water
partition of 4300 determined by Tonner et. al. [27] and
smaller than the octanol/water partition of 6165 reported
by Hansch et. al. [28]. Triglyceride should provide the best
model for tissue lipid/water partition.
The value that is used in eq. (4) for the propofol fraction
that is free in the blood (fwblood) is based on experimental
measurements of the fraction free in human plasma
(freepl), which is related to fwblood by:
where rblpl is the blood/plasma concentration ratio. In
normal subjects, freepl varies from subject to subject by
about ± 40% of the mean [14-19], primarily because of
individual variation in plasma lipids. It is assumed that
only the plasma lipid varies from subject to subject, while
the red cell lipid is constant, so that the value of the
blood/plasma ratio (rblpl) also varies for each subject as a
function of freepl:
where rblplst  and freeplst  are the mean experimental
human propofol values for the blood/plasma ratio and
the free plasma concentration and hmt is the standard
hematocrit.
To summarize the procedure that is used to determine the
tissue blood/partition coefficients for the PBPK model as
a function of the PBPK parameter freepl: 1) The blood/
plasma ratio (rblpl) is determined from eq. (7) using the
experimental values for freeplst and rblplst (see below). 2)
fwi for each tissue is determined using eq. (5) and the
standard values of Koil and vf
i. 3) fwblood is determined
from eq. (6). 4) Finally, the tissue/blood partition is deter-
mined from these values of fwi and fwblood using eq. (4).
Since the plasma propofol concentration was measured in
the experiments of Schnider et. al [20], the whole blood
model concentrations were first converted to the equiva-
lent plasma concentration before the model results were
output in the plots of plasma model concentration versus
experimental data.
Standard value for human propofol free plasma 
concentration fraction (freeplst) and blood/plasma ratio 
(rblplst)
As discussed above, the tissue/blood partition depends on
the value of the fraction free in plasma (freepl). Experi-
mental measurements of the normal human free plasma
propofol fraction (freepl) fall into two different ranges.
The smaller value of about 0.01 comes from a series of
publications by Suarez and colleagues using ultrafiltration
[14-16]. A larger value of about 0.02 has been reported by
several other research groups: Using equilibrium dialysis,
Altmayer et. al [17] reported values ranging from 0.014 to
0.026 and Servin et. al. [18] reported an average value of
0.022; while Mazoit and Samii [19] report an average
value of about 0.02 using a charcoal co-binding
Table 1: Standard human PBPK organ weights, blood flows and 
fraction lipid
Organ Weight 
(Kg)
Fraction 
Lipid
Perfusion 
(L/Kg)
Total Flow 
(L/min)
Blood 5.5 ≈ 0.01
liver 1.8 0.25 0.25 0.45
portal 1.5 0.02 0.75 1.125
muscle 26 0.017 0.0225 0.585
kidney 0.31 0.017 4 1.24
brain 1.4 0.022 0.56 0.784
heart 0.33 0.017 0.8 0.264
lung 0.536 0.017 10.482 5.6184
skin 2.6 0.017 0.1 0.26
tendon 3 0.017 0.01 0.03
other 5.524 0.017 0.02 0.1104
bone 400 0
adipose 17.5 0.8 0.0422 0.7385
Total 70 5.5877
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technique. All reports agree that the plasma binding is
independent of propofol concentration in the clinical
concentration range and that the normal individual varia-
tion is about ± 40% of the mean. Although the difference
in these measurements of the freeplst (0.01 versus 0.02) is
small in absolute value, it has a dramatic effect on the
pharmacokinetics – producing a roughly two-fold differ-
ence in the tissue/blood partition coefficient (eq. (4)).
Since the PBPK analysis (see below) is consistent with a
value of about 0.022, this was the value that was assumed
for standard values for freepl (freeplst). The reported val-
ues for the normal human blood/plasma ratio (rblplst)
vary from 1.1 to 1.3: [18,19,29,30] and a standard value
of the blood/plasma ratio (rblplst) of 1.0 was assumed.
Because of the large (40%) individual variation in freepl,
it might be regarded as an adjustable parameter that var-
ied from subject to subject. However, since it was found
that there was no significant improvement of the PBPK
model fit to the individual data when freepl was allowed
to vary, in the following analysis it is assumed that all sub-
jects had a freepl of 0.022. Using eqs. (4) – (7), the corre-
sponding normal model values for the tissue/blood
partition coefficients using the value of vf
i in Table 1 are:
adipose 84; brain 1.87; liver 2.12; intestine 1.7 and the
rest 1.45. These values are in the same range as the exper-
imental measurements of Weaver et. al. [1] after a 2 hour
constant infusion in sheep: brain 1.8 – 2.4; kidney 1.36 –
1.85; skeletal muscle 0.68 – 1.4 (the range corresponds to
the values for 2 different infusion rates). Assuming that
the propofol binding in blood is produced entirely by par-
titioning between the blood lipid and water, the freepl
value of 0.022 corresponds to a value for the fraction of
lipid in whole blood (vf
blood) of about 0.0093 (using eq.
(5)), which is in the range of the normal human blood
total lipid (total plasma lipid of 0.0082 gm/ml [31] and
blood/plasma lipid ratio of 1).
PBPK description of propofol metabolism
It is assumed that the kinetics of all the tissues are
described by a flow limited, well mixed model, except for
the liver, which is described using the "Dispersion" model
of Rowland and colleagues [32,33] with a dispersion coef-
ficient of 0.3. Measurements of brain, arterial and venous
propofol concentrations during infusions in sheep are
consistent with a flow limited, well mixed model for the
brain [34]. This well-mixed tissue assumption is only cor-
rect as a first approximation and there is some evidence
that it may not be rigorously correct for muscle [35].
Since the kinetic analysis of Schnider et. al. [20] of the
data analyzed in this paper indicated that the kinetics
were linear over the constant infusion range (25 to 200
µg/kg/min) that was investigated, a linear PBPK model is
used. It is assumed that the propofol removal is entirely
the result of liver metabolism and is described by the
intrinsic liver clearance (Tclr), defined by:
(8)   Q(x)dx = Tclr c(x) dx
where Q is the rate of liver metabolism (amount/min)
and c is the free liver tissue concentration. Since a disper-
sion model is used for the liver [32,33], the metabolism
varies as a function of distance (x) from the start of the
liver sinusoid. For the subjects investigated in this paper,
Tclr varies from about 65 to 400 liters/min/70 Kg human.
Although Tclr has units of clearance it is not equal to the
actual liver whole blood clearance for two reasons. First,
the concentration term in eq. (8) is the free liver concen-
tration, not the whole blood concentration. The effective
clearance from the blood (Tclrblood) is related to Tclr
approximately by:
(9)   Tclrblood = (water / blood partition) Tclr ≈  0.02 Tclr
A second, more complicated, correction arises from the
position dependence in eq. (8) and the fact that as Tclr
increases to infinity; the actual liver clearance rises to a
maximum equal to the liver blood flow. A more direct
measure of liver metabolism is the steady state "Fractional
Liver Clearance" defined by:
Table 2 provides a useful conversion between Tclr and
Fraction Liver Clearance for the standard human. In the
description of the PBPK model fits to the individual
subjects (figs. 5, 6, 7), both Tclr and Fraction Liver Clear-
ance are indicated. In PKQuest, either Tclrliver or the equiv-
alent Fraction Liver Clearance can be input.
Although there is evidence of extrahepatic human propo-
fol metabolism [36], it has been assumed in the PBPK
model that all the clearance results from liver metabolism.
With the exception of subject 2–4, the clearance could be
modeled by this assumption for all the subjects in the
study- that is, the clearance did not exceed the total liver
blood flow. For subject 2–4 (see fig. 6) an additional ext-
rahepatic (about 10%, assigned arbitrarily to the kidney)
metabolism was required to fit the data.
It has been assumed in the PBPK model that there is no
pulmonary propofol metabolism. This is supported by the
experiments of He et. al. [37] who found no significant
pulmonary artery – radial artery propofol concentration
difference during a constant infusion. Also, Gray et.
al.[36] found no arterial – venous difference in propofol
or propofol metabolites during the anhepatic phase of
liver transplantation. However, in opposition to these
10 1 () =− Fraction Liver Clearance
BloodConcentrationOutof Liver
Bl loodConcentrationEnteringLiverBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
Page 6 of 29
(page number not for citation purposes)
Individual PBPK model fits to the experimental data for the young subjects Figure 5
Individual PBPK model fits to the experimental data for the young subjects. The values of the 3 parameters that provided the 
best fit for each individual subject are listed: Tclr = intrinsic liver clearance; frdose = fraction of the bolus dose sequestered in 
first passage through the lung; T = time constant for release of sequestered propofol. The value in parenthesis following Tclr is 
the fraction of the total liver blood flow that is cleared (eq. (10)).
Summary: Ages 18-34 years
Infusion rate = 25 µ µ µ µg/kg/min
Subject 1-1
Tclr =226 (0.904)
frdose = 0.2
T = 500
Subject 1-5
Tclr = 132 (0.776)
frdose = 0.3
T=8 0
Subject 1-2
Tclr = 478 (0.974)
frdose = 0.4
T = 200
Subject 1-8
Tclr =174 (0.842)
frdose = 0.2
T=4 0
Subject 1-3
Tclr = 86 (0.665)
frdose = 0.6
T=8 0
Subject 1-6
Tclr = 84.6 (0.664)
frdose = 0.3
T=8 0
Subject 1-7
Tclr = 68.7 (0.647)
frdose = 0.4
T=8 0
Infusion rate = 100 µ µ µ µg/kg/min
Infusion rate = 50 µ µ µ µg/kg/min
Subject 1-4
Tclr =80.9 (0.725)
frdose = 0.3
T=8 0
Infusion rate = 200 µ µ µ µg/kg/minBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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Individual PBPK model fits to the experimental data for the middle aged subjects Figure 6
Individual PBPK model fits to the experimental data for the middle aged subjects. The values of the 3 parameters that provided 
the best fit for each individual subject are listed (see fig. 5). For 6 of the 8 subjects there was no pulmonary sequestration of the 
bolus dose. In order to fit the data for subject 2–4, a small amount of extra-hepatic metabolism was required (kidney clearance 
= Tclrkid = 35).
Summary: Ages 35-65 years
Infusion rate = 25 µ µ µ µg/kg/min
Subject 2-2
Tclr =53.5 (0.546)
Subject 2-7
Tclr =63.5 (0.574)
Subject 2-1
Tclr =63.8 (0.594)
Subject 2-5
Tclr =800 (1.0)
Subject 2-4
Tclr =229 (0.967)
Tclrkid=35
Subject 2-8
Tclr =186 (0.897)
frdose=0.25
T=60
Subject 2-3
Tclr =135 (0.811)
Subject 2-6
Tclr =136 (0.873)
frdose=0.3
T=80
Infusion rate = 50 µ µ µ µg/kg/min
Infusion rate = 100 µ µ µ µg/kg/min
Infusion rate = 200 µ µ µ µg/kg/minBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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Individual PBPK model fits to the experimental data for the old subjects Figure 7
Individual PBPK model fits to the experimental data for the old subjects. No pulmonary sequestration of the bolus dose was 
required in any subject in this age group. Therefore, there is only 1 adjustable parameter (intrinsic liver clearance, Tclr).
Summary: Ages >65 years
Infusion rate = 25 µ µ µ µg/kg/min
Subject 3-4
Tclr =88.6 (0.672)
Subject 3-5
Tclr =65.1 (0.588)
Subject 3-2
Tclr =72 (0.637)
Subject 3-7
Tclr =82 (0.738)
Subject 3-1
Tclr =241 (0.919)
Subject 3-6
Tclr =79.3 (0.721)
Subject 3-3
Tclr =86.3 (0.786) Subject 3-8
Tclr =118 (0.794)
Infusion rate = 50 µ µ µ µg/kg/min
Infusion rate = 100 µ µ µ µg/kg/min
Infusion rate = 200 µ µ µ µg/kg/minBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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experiments, Dawidowicz et. al. [38] found a significant
pulmonary arterial – venous difference for both propofol
and propofol metabolites, indicating some pulmonary
metabolism.
Pulmonary sequestration
As discussed in the Background section, the PBPK analysis
suggests that in some subjects a fraction of the bolus
propofol injection is sequestered in the lung and then
slowly released. This sequestration is described by two
parameters: 1) frdose – the fraction of the dose that is
sequestered; and 2) T – the time constant of the exponen-
tial release from the lung of the sequestered fraction. The
rate of release from the lung (R(t)) of the sequestered pro-
pofol after the bolus input is described by:
(11)   Rbolus (t) = (1/T) Dose frdose exp(-t / T)
This sequestration was incorporated into the PBPK model
simply by dividing the bolus input into two non-seques-
tered components: 1) A bolus input of Dose × (1-frdose);
and 2) An exponential input of total amount = Dose ×
frdose.
The data was also analyzed to check whether there was
sequestration of the constant infusion dose. This required
a more complicated modification. The constant infusion
was again divided into two components. The first, non-
sequestered, component was just a constant infusion of
Dose × (1-frdose). For the second, sequestered compo-
nent, it was assumed that a fraction frdose of the constant
infusion was accumulated in a well-mixed compartment
in the lung that was released with the same exponential
time course as the bolus dose. The release for the bolus
dose (eq. (11)) corresponds to the bolus response func-
tion of this sequestering lung compartment. Thus, the rate
of release (RI(t)) for an arbitrary input I(t) to this seques-
tering compartment is equal to the convolution of I(t) and
Rbolus(t):
This input is pre-programmed into PKQuest as one of the
input options and is invoked simply by calling this input
option.
Determination of PBPK parameters
Each subject in the study was given a bolus propofol injec-
tion followed 60 minutes later by a constant 60 minute
infusion and the PBPK model was used to fit the individ-
ual concentration curves. The previously determined
"standard human" PBPK parameter set (organ blood flow,
volume, etc., see Table 1) was used for all subjects. The tis-
sue/blood partition was determined from eqs. (4)–(7)
using a freepl = 0.022, a blood/plasma ratio of 1 and the
tissue lipid fractions determined previously (Table 1) [4].
The values of these standard parameters depend on the
percent body fat, which is determined using eq. (2).
For each subject the intrinsic liver clearance was adjusted
to fit the data. For some subjects, in order to fit the bolus
phase it was also necessary to choose the two parameters
describing the pulmonary sequestration (frdose and T).
Several steps were used to determine these parameters for
each subject: 1) Subjectively adjust the liver clearance
(Tclr) to fit the constant infusion phase. 2) If both the
bolus and constant infusion phase could be adequately fit
by one value of the liver clearance, than it was assumed
that there was no pulmonary sequestration and step 3 was
implemented. In 14 of the 24 subjects, no pulmonary
sequestration was required. In the other 10 subjects it was
necessary to adjust frdose and T to fit the bolus phase.
Depending on the value of T, the slow release from the
sequestered compartment can extend into the constant
infusion phase, and it was necessary to repeat this cycle of
parameter estimation. 3) Finally, a 1-parameter Powel
non-linear minimization routine in PKQuest was used to
find the value of Tclr that provided the best fit to the entire
experimental concentration curve (bolus plus constant
infusion) for that subject. This used a weighted least
square minimization technique with weights determined
by assuming that the standard deviation of the measure-
ment was proportional to the model concentration.
The experimental plasma concentration was collected
over a time course of 0 to 600 minutes, with the first data
points at 1, 2, 4 ... minutes and the last two samples at 300
and 600 minutes. Because of mixing and circulation time
effects [39], the PBPK model is not accurate at times < 2
minutes, so that the first point that was used in the
Table 2: Relationship between the intrinsic liver metabolic 
clearance (Tclr) and the fractional clearance of the total liver 
blood flow or the absolute steady state liver blood clearance for 
a standard male (20% fat, fraction free in plasma = 0.02).
Tclr (liters/min) Fraction Liver 
Blood Flow
Liver Clearance 
(liters/min)
10 0.13 0.23
50 0.47 0.846
100 0.68 1.224
200 0.86 1.548
300 0.93 1.674
400 0.962 1.731
500 0.977 1.76
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analysis was at 2 minutes. The fits to the 600 minute data
was less accurate than for the earlier data points (see figs.
5, 6, 7). The 600 minute data point has the most scatter
because the status of the subjects was not controlled dur-
ing the 300 to 600 minute time period and ambulation or
food intake during this period could produce large shifts
in the PBPK parameters, particularly muscle, liver and fat
blood flow. The quality of the fits were quantitated and
compared with the 6 parameter NONMEM fit by the use
of the "weighted residual error" (WRE) defined as the
average value of the absolute (measured – model)/model
concentration ratio
All the calculations and the graphical output were imple-
mented using the PKQuest software routine. The proce-
dures involved in using PKQuest have been described
previously [3-8]. All of the standard human PBPK param-
eters (blood flows, organ weights, etc) and the equations
for, e.g., converting freepl to tissue partition values, are
pre-programmed and do not have to be entered. The only
parameters that the user must enter are those that are
unique to the propofol study: the bolus input and con-
stant infusion rate; the experimental arterial plasma con-
centration data; the PBPK parameters weight, height, sex,
age, and Tclr, and, for subjects with pulmonary sequestra-
tion, frdose and T. All of the figures used in this paper rep-
resent standard PKQuest graphical output. [See
Additional file 1 for a sample PKQuest Maple worksheet
for one subject].
Model simulation of normal weight and obese subjects
The PBPK model parameters were chosen to simulate the
experiments of Servin et. al. [40] in which the pharmacok-
inetics of normal weight and morbidly obese subjects
were compared. The average values were used for the frac-
tion free in plasma (freepl = 0.022) and intrinsic liver
clearance (Tclr = 162 liters/min/70 kg). This value of Tclr
corresponds to a steady state liver clearance of 1.49 liters/
min or 83% of the total liver flow for the standard 70 kg
man (see Table 2). Results were compared for normal
weight subjects (fat fraction = 20%) and for the average
obese subject studied by Servin et. al. Using the reported
body weight and ideal body weight of the obese subjects,
it was estimated that they had a fat fraction of about 50%
based on the regression relationship of Rhode et. al [41]
that 69% of the weight greater than ideal weight is fat.
One significant change was made in the PBPK parameters
for the obese subjects. Adipose blood flow is heterogene-
ous, with the highest values in subcutaneous tissue and
lower values in visceral and perirenal fat [42]. It is proba-
ble that morbidly obese subjects have a lower average adi-
pose blood flow then normal weight subjects. An estimate
of the adipose blood flow can be obtained from the rela-
tionship between cardiac output and excess body weight.
The cardiac output measurements in morbidly obese sub-
jects of Alexander et. al. [43] were used to estimate an
average adipose tissue blood flow of 0.03 liters/kg, 28%
less than the standard value of 0.042 liters/kg (see Table
1). All the other PBPK parameters are identical for the nor-
mal and obese subjects. Since it is assumed in PKQuest
that liver weight is a constant fraction of non-fat body
weight, the obese subjects have a lower relative liver
weight and, therefore, a lower rate of propofol clearance
per kg body weight. Servin et. al. [40] used a stepwise infu-
sion regimen: 0.35 mg/kg/min for 5 minutes, 0.2 mg/kg/
min for 10 minutes, and 0.1 mg/kg/min for the remainder
of the 180 minute infusion. In the simulation, a constant
0.1 mg/kg/min infusion for the entire 180 minutes was
assumed. The same propofol infusion rate/kg was used in
both normal and obese subjects.
PKQuest is freely distributed at http://www.pkquest.com
Results
Pulmonary sequestration
Figure 2 shows a comparison of the PBPK model versus
the experimental data for the arterial plasma concentra-
tion for subject 1–3. The figures on the left are plotted on
an absolute scale, and those on the right on a semi-log
scale. The bottom row shows the data for just the bolus
phase (0 to 60 minutes). All subjects in the first two age
groups received the same initial bolus propofol dose (2
mg/kg), followed 60 minutes later by a 60 minute con-
stant infusion at rates varying from 25 to 200 µg/kg/min.
Subject 1–3 had a constant infusion rate of 100 µg/kg/
min, which is large enough to swamp out most of the
residual from the initial bolus. In fig. 2 the liver clearance
(Tclr) has been adjusted to optimize the fit to the constant
infusion phase (60 to 600 minutes).
It can be seen in fig. 2 that, using a value of Tclr that accu-
rately described the constant infusion phase, the model
prediction for the bolus phase is poor. The deviation
between the model and bolus data is unusual – with too
high a model concentration at early times (2, 4, 8, and 16
minutes) and too low a concentration at the 30 and 60
minutes time points. This same discrepancy in the model
prediction was noted in the original analysis of this data
by Schnider et. al.[20] using a NONMEM compartmental
model. It is impossible to explain this deviation using the
standard PBPK model. Any variation that improves the fit
to the bolus phase significantly worsens the fit to the con-
stant infusion phase.
This deviation between theory and experiment could be
explained if part of the bolus dose was sequestered in the
lung and then slowly released. The initial sequestering
would reduce the blood concentration at the early times,
while the later release would increase the concentration atBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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Error in fitting the kinetics following the bolus injection (0 to 60 minutes) using the PBPK parameters determined by fitting the  constant infusion kinetics (>60 minutes) assuming no pulmonary sequestration Figure 2
Error in fitting the kinetics following the bolus injection (0 to 60 minutes) using the PBPK parameters determined by fitting the 
constant infusion kinetics (>60 minutes) assuming no pulmonary sequestration. The solid lines are the PBPK model predictions 
and the squares are the experimental results of Schnider et. al. [20]. The top row shows the entire time course and the bot-
tom shows the first 60 minutes. Absolute concentration on left and semi-log plot of concentration versus time on right.
Comparison of PBPK model (solid line) with experimental data
(squares) for subject # 1-3.
No SequestrationBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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Effect of pulmonary sequestration of 0, 10, 25 or 50% of the continuously infused dose Figure 4
Effect of pulmonary sequestration of 0, 10, 25 or 50% of the continuously infused dose. Same experimental data as in figure 2 
with 60% sequestration of the bolus dose. The sequestered propofol is released with a time constant of 80 minutes.
Comparison of PBPK model with experimental data for subject # 1-3
60% sequestration of the bolus dose
Sequestration fraction of the constant infusion phase:
Black: frdose = 0 T=80 minutes
Green: frdose = 0.1 T=80 minutes
Red: frdose = 0.25 T=80 minutes
Blue: frdose = 0.5 T=80 minutesBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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later times. There is direct experimental support for
human pulmonary sequestration of the lipid emulsion
that is used in the propofol formulation [37,44-46] see
Discussion). Figure 3 shows that the experimental data for
the entire time course for subject 1–3 can be accurately fit
by the PBPK model if it is assumed that 60% of the bolus
dose is sequestered (= frdose) and then released with an
eighty minute time constant (T, see, eq. (11)).
The PBPK model was modified to look at whether the con-
stant infusion phase dose was also sequestered with the
same time constant (see Methods, eq. 9). Figure 4 shows
the fit for this same subject with a sequestered fraction of
0.5 (black line), 0.25 (red line) or 0.1 (green line) during
the constant infusion phase. (The sequestered fraction
during the bolus phase is 0.6). It can be seen that seques-
tering as little of 10% of the constant infusion dose signif-
icantly worsens the prediction of the PBPK model –
suggesting that there is no sequestration during the con-
stant infusion phase.
This subject (#1–3) was chosen as an illustration because
he had the largest value of sequestration. However, all the
other subjects in the younger age groups had some
sequestration (20 to 40%, fig. 5), as indicated by an
improvement in the fit to the bolus phase. In the middle
aged group, only two of the subjects had significant
sequestration (fig. 6). The subjects in the oldest group
received a bolus dose one half that of the two younger age
groups, and none of the subjects in the oldest age group
had significant sequestration (fig. 7).
PBPK analysis for 18–34 year old subjects
Figure 5 shows the semi-log plots of the PBPK arterial
plasma concentrations for the 8 young subjects at the 4
different constant infusion rates (all subjects received the
same bolus dose). It can be seen that the PBPK model pro-
vides a good description of the experimental results for
the 8 subjects over the entire range of infusion rates. The
values of the 3 adjustable PBPK parameters are listed in
the figure. The value of the intrinsic liver clearance (Tclr,
eq. (8)) ranges from 85 to 478 liters/min. As discussed
above (see Table 2), the actual liver clearance has a very
non-linear dependence on Tclr. The value in parenthesis
after Tclr in fig. 5 is the steady state fractional liver clear-
ance. This clearance provides a better indication of the
individual variation in liver clearance. The value of the
fraction of the bolus dose that is sequestered (frdose) var-
ies from 0.1 to 0.6, with 5 of the 8 subjects having a frdose
0.2 – 0.3. The value of the time constant for release of the
sequestered propofol (T) varies from 40 to 500 minutes
with 5 of the 8 subjects having a value of 80 minutes. The
fits are not very sensitive to the value of T, and differences
of ± 30 minutes are not significant. The average weighted
residual error for these subjects is 13.5% (Table 3).
PBPK analysis for 35–65 year old subjects
Figure 6 shows the semi-log plots of the PBPK model for
the 8 middle-aged subjects at the 4 different constant infu-
sion rates. Pulmonary sequestration of the bolus dose was
decreased for this age group. In 6 of the 8 subjects, the fits
were only slightly improved by adding sequestration, and,
to minimize the number of adjustable parameters, it was
assumed that sequestration was negligible. A sequestered
component is clearly present only for the two subjects 2–
6 and 2–8. The propofol kinetics for the other 6 subjects
in fig. 6 can be satisfactorily fit by a PBPK model with just
one adjustable parameter – Tclr. The range of values for
both these parameters are similar to those in the younger
age group (fig. 5). For one subject in this group (# 2–4) it
was necessary to add an additional renal clearance in
order to fit the data. The weighted residual error is 16.1%
(Table 3).
Table 3: Comparison of the "average weighted residual" percent error for the PBPK model (this paper) and the 6 parameter 
NONMEM model of Schnider et. al. [20]. The PBPK model fits were for both the bolus and the constant infusion input phases, while 
the NONMEM model fit was for just the constant infusion phase. The PBPK model results are subdivided into the different age groups. 
The column labeled "Individual Fits" is the error when the model parameters were adjusted for each subject (see figs. 4–6). The 
column labeled "Average Fits" is the error when one parameter set with a linear age dependence for the fraction of pulmonary 
sequestration (eq. (13)) was used for all subjects (see figs. 9–11). The "Average Fit" error for the NONMEM model is listed for the case 
where the same set of 6 parameters were used for all subjects ("No Covariates") or an additional 5 covariate parameters (e.g. weight, 
height, age, etc) were used ("Covariates").
PBPK Model Bolus + Infusion Age Group Individual Fits Average Fits
18–34 years 13.5% 18.5%
35–65 years 16.1% 23.8%
>65 15.4% 17.6%
Average 15.0% 20.0%
NONMEM Model Infusion Only [20] 14.18% 23% No Covariates 17.39% 5 CovariatesBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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Same experimental data as in figure 2 except that 60% of the bolus dose has been sequestered in the lung and released with a  time constant of 80 minutes Figure 3
Same experimental data as in figure 2 except that 60% of the bolus dose has been sequestered in the lung and released with a 
time constant of 80 minutes.
Comparison of PBPK model (solid line) with experimental data
(squares) for subject # 1-3.
Sequestration: frdose = 0.6; T = 80 minutesBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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PBPK analysis for subjects older then 65 years
Figure 7 shows the semi-log plots of the PBPK model for
the 8 subjects in the >65 year old group at the 4 different
constant infusion rates. These subjects were given a bolus
dose of 1 mg/kg, half the value of the bolus dose for the
younger subjects. Since there was no evidence of pulmo-
nary sequestration in any of these 8 older subjects, the
PBPK model required only one adjustable parameter
(Tclr). The weighted residual error was 15.4% (Table 3).
Age dependence of PBPK parameters and model 
predictions using "averaged" parameters
Table 4 lists, for the 3 age groups, the average values of the
age, steady state fractional liver clearance, the intrinsic
liver clearance (Tclr) and the fraction of the bolus dose
sequestered in the first pass through the lung (frdose).
There is no significant dependence of liver clearance on
age. The fraction sequestered (frdose) decreases with age
and a linear dependence was determined (see fig. 8).
The oldest subject group (>65) was not used in this frdose
correlation calculation because they received only half the
bolus dose of the other subjects and there was no signifi-
cant sequestration (see Discussion).
Figures 9, 10, 11 show the accuracy of the PBPK model
predictions when just one set of "averaged" PBPK param-
eters is applied to all the subjects. The "averaged"
parameters are: 1) Fractional liver clearance = 0.76; 2)
Sequestration time constant = 80 minutes; and 3) fraction
pulmonary sequestration described by eq. (13). The
Age dependence of the fraction sequestered in lung Figure 8
Age dependence of the fraction sequestered in lung. The dashed line is the linear regression for the data (eq. (13)).
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Table 4: Age dependence of steady state fractional liver blood 
flow clearance (Liver Clearance), the intrinsic liver clearance 
(Tclr), and fraction of bolus dose sequestered in lung (frdose).
Age (years) Liver Clearance Tclr (liters/min) frdose
29.125 0.772 165 0.3
52.5 0.781 208 0.06875
74.75 0.762 104 0BMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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weighted residual error using these "averaged" values is
listed in Table 3.
Discussion and conclusions
Pulmonary sequestration
The pharmacokinetic evidence for this sequestration
comes from a comparison of the kinetics after the bolus
injection versus a constant infusion. It was clearly
recognized in the original analysis of this data by Schnider
et. al. [20] that there was some systematic difference
between the kinetics for these two different inputs. Sch-
nider et. al. fit the constant infusion phase kinetics for
each subject with a 6 parameter NONMEM model. When
these kinetic parameters for the infusion phase were used
to fit the initial bolus kinetics, the predicted
concentrations for the early time points (2 to 4 minutes)
were about 50% greater then the experimental values,
while the predicted concentration for the later data points
(>8 minutes) were about 50% less than the experimental
values. The same systematic difference is seen in the
younger subjects when the PBPK parameters for the con-
stant infusion phase are used to predict the concentration
following the bolus dose (fig. 2).
Pulmonary sequestration of the bolus dose with a slow
release provides an explanation of this systematic differ-
ence. The sequestration will reduce the concentration of
the early time points and, as the sequestered dose is slowly
released, increase the concentration of the later time
points. A simple model in which a fraction (frdose) of the
bolus dose is sequestered and is then released as a single
exponential (eq. (11)) provides a good fit to the
experimental data (fig. 3, and figs 5, 6, 7). The fraction of
the dose that was sequestered was largest in the younger
age group, ranging from 0.2 to 0.6 (fig 5).
As described in fig. 4, there does not seem to be any signif-
icant sequestration when the propofol is given as a
constant infusion because its subsequent slow release
would produce a significant deviation of the model pre-
dictions from the observed experimental data. This sug-
gests that the sequestration depends on the concentration
of the emulsion when it is mixed with the venous blood
at the injection site. The bolus injection rate of 140 mg/70
kg/20 sec propofol in Diprivan corresponds to an injec-
tion of about 4.2 gm/min of lipid into the vein of a 70 kg
man. In contrast, the highest rate of constant infusion (14
mg/70 kg/min) represents a 30-fold lower infusion rate.
There is direct experimental evidence for pulmonary
sequestration of propofol following a bolus injection in
humans [37,45]. He et. al.[37] simultaneously injected
propofol and indocyanine green (ICG) in a central vein
and sampled radial arterial blood at 1 second intervals for
a period of 1 minute – the first pass time. They injected 5
mg/70 kg propofol within 1 second – about twice the rate
of the bolus injection of Schnider et. al. [20] that was fit
with the PBPK model. A first pass pulmonary clearance of
propofol of about 28% was estimated from the difference
in the first pass AUC of propofol and ICG. This analysis
cannot distinguish between pulmonary metabolism ver-
sus sequestration. However, in the same study, He et. al.
[37] demonstrated that there was no significant difference
in the radial and pulmonary artery concentrations during
a 60 minute constant infusion, indicating that propofol is
neither metabolized nor sequestered during a constant
infusion.
In the standard propofol formulation (Diprivan), the pro-
pofol is dissolved in a lipid emulsion that is identical to
the emulsion (Intralipid) that is used for parenteral feed-
ing. There is also direct evidence that Intralipid is seques-
tered in the human pulmonary circulation. Zauner et. al.
[44] measured the brachial artery – pulmonary artery con-
centration difference of Intralipid during and after a con-
stant infusion. At high rates of Intralipid infusion (about
6.5 times the maximum rate used by Schnider et. al. [20])
they observed a significant pulmonary sequestration of
about 20% during the infusion, with a subsequent release
of the sequestered Intralipid that persisted for at least 15
minutes after stopping the infusion. In addition, Gigon et.
al. [46] found fat in the lumen of pulmonary capillaries in
human lung biopsies a few minutes after beginning Intral-
ipid infusion.
There are large individual variations in the model predic-
tions of the fraction of the dose that is sequestered, vary-
ing from 0 to 60%. All of the younger subjects had some
sequestration (fig. 5) with a median value of about 30%.
Only two of the eight middle-aged subjects (fig. 6) and
none of the subjects in the oldest group (fig. 7) had signif-
icant sequestration. This variation cannot be explained by
experimental variations in the bolus infusion rate, which
was carefully controlled. The lack of sequestration in the
oldest subjects might be explained, in part, because they
received only half the bolus dose of the other two groups.
Variation in sequestration could result in significant vari-
ations in the pharmacodynamic effect of a bolus propofol
injection.
This new evidence supporting the concept of pulmonary
sequestration is indirect since it is based just on an analy-
sis of the PBPK model. There clearly is a need for more
direct experimental measurements to either confirm or
rule out this effect. In addition, the predicted differences
in the magnitude of the sequestration between the young
and middle-aged subjects is a surprising result and one
that requires further documentation.BMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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PBPK model fits to the experimental data for the young subjects using the same age dependent parameters for all subjects:  fractional liver clearance = 0.76; fraction sequestered described by eq. (13), and T = 80 minutes Figure 9
PBPK model fits to the experimental data for the young subjects using the same age dependent parameters for all subjects: 
fractional liver clearance = 0.76; fraction sequestered described by eq. (13), and T = 80 minutes.
Ages 18-34 years
Averaged Parameters: Fraction sequestered = 0.548 – 0.00891 Age
Fractional liver clearance = 0.76
Infusion rate = 25 µ µ µ µg/kg/min
Subject 1-1 Subject 1-5
Subject 1-2 Subject 1-8
Infusion rate = 50 µ µ µ µg/kg/min
Infusion rate = 100 µ µ µ µg/kg/min
Subject 1-3
Subject 1-6
Infusion rate = 200 µ µ µ µg/kg/min
Subject 1-4
Subject 1-7BMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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PBPK model fits to the experimental data for the middle-aged subjects using the same age dependent parameters for all sub- jects (see fig. 9) Figure 10
PBPK model fits to the experimental data for the middle-aged subjects using the same age dependent parameters for all sub-
jects (see fig. 9).
Ages 35-65 years
Averaged Parameters: Fraction sequestered = 0.548 – 0.00891 Age
Fractional liver clearance = 0.76
Infusion rate = 25 µ µ µ µg/kg/min
Subject 2-2 Subject 2-7
Infusion rate = 50 µ µ µ µg/kg/min
Subject 2-1 Subject 2-5
Infusion rate = 100 µ µ µ µg/kg/min
Subject 2-4 Subject 2-8
Infusion rate = 200 µ µ µ µg/kg/min
Subject 2-3
Subject 2-6BMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
Page 19 of 29
(page number not for citation purposes)
PBPK model fits to the experimental data for the old subjects using the same age dependent parameters for all subjects (see fig.  9) Figure 11
PBPK model fits to the experimental data for the old subjects using the same age dependent parameters for all subjects (see fig. 
9).
Ages >65 years
Averaged Parameters: No pulmonary sequestration
Fractional liver clearance = 0.76
Infusion rate = 25 µ µ µ µg/kg/min
Subject 3-4 Subject 3-5
Infusion rate = 50 µ µ µ µg/kg/min
Subject 3-2 Subject 3-7
Infusion rate = 100 µ µ µ µg/kg/min
Subject 3-1 Subject 3-6
Infusion rate = 200 µ µ µ µg/kg/min
Subject 3-3
Subject 3-8BMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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Validity of the PBPK propofol model
The PBPK model (fig. 1) requires assumptions about a
large number of physiological parameters, such as tissue
volumes and flows, and is limited by many simplifying
assumptions, such as that the tissue regions are well
stirred (except for the liver) and flow limited. The usual
criticism of the PBPK approach is that, since it uses a large
number of adjustable "physiological" parameters that
cannot be directly measured, it becomes, in effect, a glori-
fied compartmental model. This criticism applies particu-
larly to the tissue/blood partition coefficients of the
different organs, which are impossible to directly measure
in humans. The major goal in the development of
PKQuest is to address this criticism by the development of
a "standard human" PBPK data set whose values have
been refined by application to more than 25 different sol-
utes with a wide range of pharmacokinetic properties [3-
6,8].
This propofol PBPK analysis uses the previously deter-
mined "standard human" data set for the organ volumes
and blood flows so that these parameters are no longer
"adjustable". Because of the very high propofol fat parti-
tion, the tissue/blood partition is dominated by the parti-
tion into the tissue and blood fat. In this PBPK analysis,
the tissue/blood partition was directly determined using
the tissue fat fractions that were derived in a previous
PBPK analysis of the volatile anesthetics [4] along with the
experimental value for the propofol fraction unbound in
blood (freepl = 0.022), and no other assumptions or
adjustable parameters were required. Thus, in this PBPK
model there is only one new adjustable parameter
required to completely describe the blood concentration
curves – the intrinsic liver clearance. (Two additional
parameters are required to describe the sequestration of
the bolus dose in some subjects).
The very high fat solubility of propofol makes it an ideal
candidate for a PBPK model. The partition of propofol in
tissue fat dominates the tissue/blood partition coefficient,
allowing one to estimate the tissue/blood partition simply
from knowledge of the tissue fat fraction. For other less fat
soluble solutes, the tissue/blood partition cannot be
predicted by this a priori approach, and the number of
poorly characterized adjustable PBPK parameters is mark-
edly increased.
Comparison of PBPK and compartment models
Although compartmental and PBPK models are often
regarded as competitors, they are actually complementary
and serve different purposes. Compartment models, as
implemented in NONMEM, provide an unbiased para-
metric description of a data set using a using a minimal
number of model assumptions. If one is only interested in
a parametric description of a given clinical data set, then
this is all that is needed. The limitation of the compart-
ment model is that the parameters are only weakly related
to physiological variables. One cannot use a compartment
model to predict the pharmacokinetics under varying
physiological conditions, such as changes in portal, mus-
cle or fat blood flow, or variations in plasma protein bind-
ing or body fat content.
This paper describes one of the few quantitative compari-
sons of PBPK and compartmental models that is available
in the literature. Table 3 compares the average weighted
residual percent error (WRE) for each subject using the 6
parameter NONMEM compartment model versus the 1
parameter PBPK model (for some subjects 2 additional
parameters are required to fit the bolus phase). The WRE
for the compartment model are for the fits to just the
constant infusion phase, while the WRE for the PBPK
model is for both the bolus and infusion phase. The
quality of the fits for the PBPK model is slightly poorer
than that for the NONMEM compartmental model (com-
partment model: 14.18% error; PBPK model: 15.0%
error).
The clinically important measure of the quality of the fit is
how well it predicts the kinetics using "averaged" param-
eters without any prior information about the individual
model parameters. Two different "averaged" errors were
reported for the NONMEM model (Table 3). The error
was 23% when an identical "optimal" set of 6 parameters
was used for all subjects. The error was reduced to 17.39%
when 5 "covariate" parameters were used that were based
on the subjects' sex, weight, height and age. The ability to
calculate these covariate parameters is one of the major
strengths of NONMEM compartmental modeling.
Although some PBPK models have been developed that
allow Bayesian population modeling [47], this is not pos-
sible with the current version of PKQUEST. Thus, it is not
possible to determine the covariate dependence of the
PBPK model parameter (Tclr, frdose, T) on subject's age,
weight, etc. The only correlation that was investigated for
the PBPK model was the age dependence of the
parameters (Table 4, fig. 8). The only parameter with sig-
nificant age dependence was the pulmonary sequestration
fraction (fig. 8). Using this linear age dependent correla-
tion (eq. (13)) an "averaged" PBPK model fit was
obtained for all subjects (figs. 9, 10, 11). These calcula-
tions also include a limited correlation for sex, age, weight
and height through the use of an estimate of each subject's
percent body fat using eq. (2). For the PBPK model, the
"average" error was 20.0%, significantly worse than the
covariate NONMEM model error of 17.39%. It should be
emphasized that the PBPK model error is for both the
bolus and constant infusion phases, while the NONMEM
error is for just the constant infusion phase.BMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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An important limitation of the NONMEM compartmental
approach is that, since it is only a parametric description
of a particular data set, errors may occur when the model
is extrapolated beyond this data set. This is clearly illus-
trated for propofol if one tries to extrapolate the compart-
mental model to times longer than those used in the
experimental data set (10 hours). The time constant (T)
for equilibration with adipose tissue is described by:
For an adipose blood flow of 0.042 ml/gm/min and an
adipose/blood partition coefficient of 84, T is 2000 min-
utes, or 33.3 hours. Accurate estimates of steady state
clearance (Clss) and volume of distribution (Vss) require
that the kinetics be determined for times of about twice
that of the longest time constant, eg. about 50 hours. Most
kinetic studies are for periods much shorter than this and
have led to misleading values for these parameters. This is
clearly illustrated by the NONMEM compartmental anal-
ysis of Schnider et. al. [20]. Based on measurements for a
10 hour sample period, they found a Vss of about 260 lit-
ers, about 10 times less than the Vss of 1200 to 3940 liters
obtained by Campbell et. al. [48], Morgan et. al. [49] and
Albanese et. al. [50] using plasma values sampled for
times varying from 40 to 100 hours. In addition, Schnider
et. al. [20] estimated a Clss of 1.89 liters/min, significantly
larger than the experimental estimates of Campbell et. al.
[48] and Morgan et. al. [49] of 1.02 to 1.6 liters [48,49].
In contrast, a much better estimate of Vss  and Clss is
obtained using the PBPK model. For the standard human
(20% fat) the Vss for the PBPK model is about 1500 liters,
of which about 97% is contributed by the adipose tissue.
For body fat varying from 12% to 40%, the PBPK model
Vss varies from 980 to 3000 liters, in good agreement with
the experimental measurements of Campbell et. al. [48]
and Morgan et. al. [49]. The intrinsic clearance, Tclr, (eq.
(8)), varies from about 70 to 500 liters/min with a median
value of about 160 liters/min (Table 4). This corresponds
to a median value for the steady state liver clearance of
about 1.49 liters/min/70 kg, with a range of 1 to 1.8 liters/
min (Table 2), which, again, is similar to what is observed
experimentally [48,49].
A direct comparison of the PBPK and NONMEM model
predictions is shown in fig. 12 (standard male, 21% body
fat) and fig 13 (obese female, 47% body fat). The PBPK
model used the average Tclr value for the young subjects
(Tclr = 165) with the body fat determined using the sub-
jects age, weight and height (eq. (2)). The top row
compares the model predictions for a 1-hour constant
infusion followed by a 9-hour washout. Both models give
very similar results over this limited washout time. This is
expected since this is the time period for which the NON-
MEM and PBPK parameters were optimized. The differ-
ences in the two models become dramatic if the washout
is extended to 49 hours (fig. 12 and 13, middle row), long
enough for differences in the value of Vss  to become
important. This underestimate of Vss  has important
clinical implications, which are illustrated in the bottom
row of figs. 12 and 13 for the case of a constant 5-day infu-
sion, mimicking the use of propofol for long term seda-
tion. As can be seen in fig. 12, for the standard male (21%
fat) the predicted steady state plasma value using the
NONMEM model is about 19% less than that for the
PBPK model using the "correct" value of Vss. This differ-
ence becomes significantly greater (53%) in obese sub-
jects (fig. 13) with a larger adipose compartment.
Physiological implications – body fat fraction
The major advantage of an accurate PBPK model is that it
can be used to predict the pharmacokinetics for varying
physiological conditions. The primary application of the
PBPK approach has been in the field of toxicokinetics
where the ability to predict the kinetics under varying
physiological conditions is critical (for a recent review, see
[51]). The usefulness of these PBPK predictions is criti-
cally dependent on having confidence that the PBPK
model is not just a set of adjustable parameters but,
instead, represents a true "physiologically based model"
that can be extrapolated to conditions that are different
from those that were used to derive the model parameters.
The fact that this propofol PBPK model has just one new
adjustable parameter (liver clearance), helps to justify this
confidence.
This section will focus on one physiological variable – the
body fat fraction. The property that most distinguishes the
propofol kinetics is its very high oil/water partition coeffi-
cient of about 4715. The corresponding adipose/blood
partition coefficient is about 84 (eq. (4) which results in a
huge volume of distribution, about 2000 liters/70 kg, of
which about 97% is in the adipose tissue. One might
expect that the body fat content should have a large
influence on the kinetics. However, Servin et. al. [40]
compared the propofol kinetics for normal weight and
morbidly obese subjects during standard surgical anesthe-
sia (180 minute constant infusion of 0.1 mg/kg/min fol-
lowed by an 8 hour washout) and showed that the
differences in the two groups of subjects was small. Figure
14 shows a PBPK model simulation of the experiments of
Servin et. al. (see Methods for details). The black line is for
a normal subject (20% body fat) and the red is for the
average morbidly obese subject (50% body fat). Servin et.
al. followed the washout for 8 hours after stopping the
infusion (fig. 14, top panel). It can be seen that over most
of the infusion and washout period, the concentrations in
the obese subjects differs by less than 30% from that for
T
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Comparison of NONMEM (Schnider et. al., Table 2 [20]) and PBPK model predictions for a standard male (21% body fat, age  53, weight 77 kg and height 177 cm) Figure 12
Comparison of NONMEM (Schnider et. al., Table 2 [20]) and PBPK model predictions for a standard male (21% body fat, age 
53, weight 77 kg and height 177 cm). The top row shows the model predictions for a 1-hour constant infusion of 100 µg/kg/
min followed by a 9 hour washout (left, absolute plot; right, semi-log plot). The middle row shows the model predictions when 
the washout period is extended to 49 hours. The bottom row compares the model predictions for a 5 day constant infusion of 
100 µg/kg/min.
Comparison of PBPK (black) and NONMEM (red) model
Male: 21% FatBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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Same as fig. 12, except for an obese female with 47% body fat (age 53, weight 77 kg and height 150 cm) Figure 13
Same as fig. 12, except for an obese female with 47% body fat (age 53, weight 77 kg and height 150 cm).
Comparison of PBPK (black) and NONMEM (red) model
Female: 47% FatBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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Comparison of arterial blood concentration in normal weight (black) and morbidly obese subjects (red) Figure 14
Comparison of arterial blood concentration in normal weight (black) and morbidly obese subjects (red). The propofol was 
infused at a constant rate of 0.1 mg/kg/min for 180 minutes and the washout was followed for 8 hours (top panel) or 5 days 
(bottom panel).
Comparison of normal weight (black) and obese subject (red) kinetics
Five day washout
Eight hour washoutBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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the normal subjects, which is small compared to the inter-
individual variation in the experimental study of Servin et.
al. Thus, this model simulation is consistent with the
main conclusion of Servin et. al. that variations in body
fat content have relatively small effects on the propofol
kinetics during standard surgical procedures. However, if
the washout is followed for 5 days, a period that is long
Comparison of time for eye opening after a 180 minute constant infusion in normal weight (black) and morbidly obese subjects  (red) Figure 15
Comparison of time for eye opening after a 180 minute constant infusion in normal weight (black) and morbidly obese subjects 
(red). Same conditions as fig. 14, but only the first 20 minutes of the washout is plotted. The dashed line indicates the arterial 
concentration associated with the first eye opening.
Eye Opening Concentration
Comparison of normal weight (black) and obese subject (red):
Early washout kineticsBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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compared to the 33 hour adipose time constant, the dif-
ference in kinetics for the obese subjects becomes dra-
matic (fig. 14, bottom panel).
The most significant difference that was observed by
Servin et. al. [40] for the obese subjects is that they woke
up significantly faster than the normal weight subjects
after stopping the propofol infusion. Figure 15 shows the
first 20 minutes of the washout period after the 180-
minute propofol infusion. Servin et. al. recorded the time
and arterial blood concentration of first eye opening. The
eye opening arterial blood concentration was the same for
obese and normal subjects (about 1 mg/l; fig. 15, dashed
line). The model simulation in fig. 15 predicts an eye
opening time of about 5 minutes for the obese subjects
and 13 minutes for the normal subjects. This is
qualitatively similar to what was observed by Servin et. al.
(obese: 10.3 ± 6.3 minutes; normal: 18.4 ± 5.7 minutes).
Comparison of arterial blood concentration in normal weight (black) and morbidly obese subjects (red) Figure 16
Comparison of arterial blood concentration in normal weight (black) and morbidly obese subjects (red). Ten-day constant infu-
sion of 0.1 mg/kg/min.
Comparison of normal weight (black) and obese subject (red):
10 Day Constant InfusionBMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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Propofol is routinely used for long-term sedation. Figure
16 shows the model simulation of the arterial concentra-
tion for a 10-day constant infusion of 0.1 mg/kg/min in
normal weight and morbidly obese subjects. It can be seen
that for these long-term infusions, the pharmacokinetics
in obese subjects differs significantly from normal sub-
jects. In normal weight subjects the arterial concentration
reaches a steady state value after about 3 days, while in the
Comparison of washout kinetics in normal weight (black) and morbidly obese subjects (red) Figure 17
Comparison of washout kinetics in normal weight (black) and morbidly obese subjects (red). The 10 day constant infusion rate 
has been adjusted so that the concentration at the end of 10 days is identical for the normal and obese subjects (normal: 0.1 
mg/kg/min; obese: 0.058 mg/kg/min). Only the first 60 minutes of the washout is plotted.
Comparison of normal weight (black) and obese subject (red):
Washout after 10 Day Constant Infusion
(Infusion rate adjusted to establish identical arterial concentration at day 10)BMC Anesthesiology 2005, 5:4 http://www.biomedcentral.com/1471-2253/5/4
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obese subjects the arterial concentration is still rising at
the end of the 10 day infusion. The arterial propofol rises
to a higher concentration in the obese subjects because
the same dose/kg was given to both subjects, while the
obese subject has a lower rate of liver metabolism/kg
because of the assumption of a constant liver weight per
lean body mass. Probably the most important clinical
implication of this model analysis is the prediction the
kinetics of the washout phase after long-term sedation.
Figure 17 shows the model simulation of the first 60
minutes of washout after a 10 day constant infusion. The
infusion rate has been adjusted so that the normal and
obese subjects have identical arterial concentrations just
before the infusion is stopped. Sixty minutes after stop-
ping the infusion the arterial concentration in obese sub-
jects has dropped to a value of only 65% of the 10-day
value, versus 45% in normal subjects. This suggests that
blood concentrations during long-term infusions in obese
subjects must be carefully monitored to assure rapid
awakening when the infusion is terminated.
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